SLC7A11 and hepatocellular carcinoma: found that activation of the PI3K/AKT/NRF2 axis in sorafenib-resistant advanced hepatocellular carcinoma cells significantly upregulated ABCC5 expression, while stabilizing solute carrier family 7 member 11 (SLC7A11) protein and increasing intracellular glutathione (GSH) content, thereby inhibiting ferroptosis (26).